EDIGENE INC.

In News

EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies - Business Wire

Business Wire - Nov 07, 2022

Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Sep 15, 2021

EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs - Business Wire

Business Wire - Feb 08, 2022

Researchers Develop “Off-the-Shelf” CAR T-Cell Therapy - Technology Networks

Technology Networks - Sep 09, 2025

Some of the Key Players in Next Generation Genome Editing Market: - Insightace Analytic

Insightace Analytic - Oct 22, 2024

Tackling rare genetic diseases with own genome editing technology | Entrepreneurs 01 - 東京大学

東京大学 - Jan 15, 2021

Genome Editing Firm EdiGene Raises $10M in Series Pre-B Plus Financing Round - Genome Web

Genome Web - Feb 05, 2019

Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval - Clinical Trials Arena

Clinical Trials Arena - Jan 17, 2024

Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Jul 26, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment